| Description | ST7612AA1 is a novel potent and oral HDCA inhibitor that acts as an HIV-1 latency reactivator. ST7612AA1 showed significant antitumor activity at low concentrations in vitro and in vivo. ST7612AA1 has potential anticancer activity and can be used to study malaria. |
| molecular weight | 405.51 |
| Molecular formula | C20H27N3O4S |
| CAS | 1428535-92-5 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 55 mg/mL (135.63 mM) |
| References | 1. Vesci L,et al. Preclinical antitumor activity of ST7612AA1: a new oral thiol-based histone deacetylase (HDAC) inhibitor. Oncotarget. 2015 Mar 20;6(8):5735-48. 2. Giannini G,et al. ST7612AA1, a thioacetate-ω(γ-lactam carboxamide) derivative selected from a novel generation of oral HDAC inhibitors. J Med Chem. 2014 Oct 23;57(20):8358-77. |